R Squared’s Black Diamond Therapeutics BDTX Stock Holding History

R Squared’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,139	Closed	-$25.1K	–	564
2025 Q2	$25.1K	Buy	+10,139	New	+$19.5K	0.01%	433
2025 Q1	–	Sell	-1,430	Closed	-$3.06K	–	434
2024 Q4	$3.06K	Buy	+1,430	New	+$4.1K	﹤0.01%	1409

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

R Squared's BDTX Position: Q3 2025 in Review

R Squared sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 10,139 shares — an estimated $25.1K sold.

R Squared first reported a position in BDTX in Q4 2024 and held it in 2 quarters. The position peaked at $25.1K in Q2 2025. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

R Squared reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
R Squared sold 10,139 Black Diamond Therapeutics shares in Q3 2025, an estimated $25.1K.
R Squared first reported a position in Black Diamond Therapeutics in Q4 2024 and held it in 2 quarters.
R Squared's Black Diamond Therapeutics position peaked at $25.1K in Q2 2025.
91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.